BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 23886209)

  • 1. Serum gastrin and the pepsinogen I/II ratio as markers for diagnosis of premalignant gastric lesions.
    Shafaghi A; Mansour-Ghanaei F; Joukar F; Sharafkhah M; Mesbah A; Askari K; Geranmayeh S; Mehrvarz A; Souti F; Sokhanvar H; Fakhrieh S; Aminian K; Yousefi-Mashhour M; Khosh-Sorur M; Rasoulian J
    Asian Pac J Cancer Prev; 2013; 14(6):3931-6. PubMed ID: 23886209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The correlation between histological gastritis staging- 'OLGA/OLGIM' and serum pepsinogen test in assessment of gastric atrophy/intestinal metaplasia in China.
    Wang X; Lu B; Meng L; Fan Y; Zhang S; Li M
    Scand J Gastroenterol; 2017 Aug; 52(8):822-827. PubMed ID: 28436254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Detection of gastric preneoplastic lesions with serum levels of pepsinogen in Chilean subjects].
    Fernández F JI; de Aretxabala U X; Santander D R; Sabah T S; Maira S J; Navarro R A; Planzer D M; Gómez L F; Etchart M; Gallegos I; Torrens X; Fasce P G; Reydet I
    Rev Med Chil; 2007 Dec; 135(12):1519-25. PubMed ID: 18357351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic values of serum levels of pepsinogens and gastrin-17 for screening gastritis and gastric cancer in a high risk area in northern Iran.
    Nejadi-Kelarijani F; Roshandel G; Semnani S; Ahmadi A; Faghani B; Besharat S; Akhavan-Tabib A; Amiriani T
    Asian Pac J Cancer Prev; 2014; 15(17):7433-6. PubMed ID: 25227854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening of precancerous gastric lesions by serum pepsinogen, gastrin-17, anti-helicobacter pylori and anti- CagA antibodies in dyspeptic patients over 50 years old in Guilan Province, north of Iran.
    Mansour-Ghanaei F; Joukar F; Rajpout Y; Hasandokht T
    Asian Pac J Cancer Prev; 2014; 15(18):7635-8. PubMed ID: 25292040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum pepsinogen I, pepsinogen II, and gastrin 17 in relatives of gastric cancer patients: comparative study with type and severity of gastritis.
    Haj-Sheykholeslami A; Rakhshani N; Amirzargar A; Rafiee R; Shahidi SM; Nikbin B; Khosravi F; Massarrat S
    Clin Gastroenterol Hepatol; 2008 Feb; 6(2):174-9. PubMed ID: 18237867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accuracy and cut-off values of pepsinogens I, II and gastrin 17 for diagnosis of gastric fundic atrophy: influence of gastritis.
    Nasrollahzadeh D; Aghcheli K; Sotoudeh M; Shakeri R; Persson EC; Islami F; Kamangar F; Abnet CC; Boffetta P; Engstrand L; Dawsey SM; Malekzadeh R; Ye W
    PLoS One; 2011; 6(10):e26957. PubMed ID: 22066020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temporal changes in serum biomarkers and risk for progression of gastric precancerous lesions: a longitudinal study.
    Tu H; Sun L; Dong X; Gong Y; Xu Q; Jing J; Long Q; Flanders WD; Bostick RM; Yuan Y
    Int J Cancer; 2015 Jan; 136(2):425-34. PubMed ID: 24895149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validity of serum pepsinogen I/II ratio for the diagnosis of gastric epithelial dysplasia and intestinal metaplasia during the follow-up of patients at risk for intestinal-type gastric adenocarcinoma.
    Dinis-Ribeiro M; da Costa-Pereira A; Lopes C; Barbosa J; Guilherme M; Moreira-Dias L; Lomba-Viana H; Silva R; Abreu N; Lomba-Viana R
    Neoplasia; 2004; 6(5):449-56. PubMed ID: 15548353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Serological Biopsy Using Five Stomach-Specific Circulating Biomarkers for Gastric Cancer Risk Assessment: A Multi-Phase Study.
    Tu H; Sun L; Dong X; Gong Y; Xu Q; Jing J; Bostick RM; Wu X; Yuan Y
    Am J Gastroenterol; 2017 May; 112(5):704-715. PubMed ID: 28323271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pepsinogen and gastrin in the noninvasive diagnosis of gastric atrophy. A case-control study in Peruvian population].
    Colarossi A; Inga R; Prochazka R; Reyes U; Bussalleu A; Barúa RL
    Rev Gastroenterol Peru; 2011; 31(2):110-5. PubMed ID: 21836650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serological assessment of gastric intestinal metaplasia and atrophy using pepsinogen-I, pepsinogen-II and gastrin-17 levels in a low incidence area of gastric cancer endemic for H. pylori infection.
    Ghoshal UC; Kumar S; Krishnani N; Kumari N; Chourasia D; Tripathi S
    Trop Gastroenterol; 2011; 32(4):292-8. PubMed ID: 22696910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The association between precancerous gastric lesions and serum pepsinogens, serum gastrin, vascular endothelial growth factor, serum interleukin-1 Beta, serum toll-like receptor-4 levels and Helicobacter pylori Cag A status.
    Yakut M; Örmeci N; Erdal H; Keskin O; Karayel Z; Tutkak H; Soykan I
    Clin Res Hepatol Gastroenterol; 2013 Jun; 37(3):302-11. PubMed ID: 23137754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic value of serum pepsinogen I, pepsinogen II, and gastrin-17 levels for population-based screening for early-stage gastric cancer.
    Wang Y; Zhu Z; Liu Z; Zhao Z; Xue X; Li X; Li P; Rong G; Ma Y
    J Int Med Res; 2020 Mar; 48(3):300060520914826. PubMed ID: 32228342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Basal and stimulated gastrin and pepsinogen levels after eradication of Helicobacter pylori: a 1-year follow-up study.
    Gisbert JP; Boixeda D; Al-Mostafa A; Vila T; de Rafael L; Alvarez Baleriola I; de Argila CM; Abraira V
    Eur J Gastroenterol Hepatol; 1999 Feb; 11(2):189-200. PubMed ID: 10102232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical utility of serum pepsinogen levels as a screening test of atrophic gastritis].
    Chae H; Lee JH; Lim J; Kim M; Kim Y; Han K; Kang CS; Shim SI; Kim JI; Park SH
    Korean J Lab Med; 2008 Jun; 28(3):201-6. PubMed ID: 18594172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma ghrelin concentration correlates with the levels of serum pepsinogen I and pepsinogen I/II ratio--a possible novel and non-invasive marker for gastric atrophy.
    Suzuki H; Masaoka T; Hosoda H; Nomura S; Ohara T; Kangawa K; Ishii H; Hibi T
    Hepatogastroenterology; 2004; 51(59):1249-54. PubMed ID: 15362725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histologic and serum risk markers for noncardia early gastric cancer.
    Shiotani A; Iishi H; Uedo N; Kumamoto M; Nakae Y; Ishiguro S; Tatsuta M; Graham DY
    Int J Cancer; 2005 Jun; 115(3):463-9. PubMed ID: 15688378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes with aging in gastric biomarkers levels and in biochemical factors associated with
    Shan JH; Bai XJ; Han LL; Yuan Y; Sun XF
    World J Gastroenterol; 2017 Aug; 23(32):5945-5953. PubMed ID: 28932086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Correlation of serum pepsinogen level and gastric mucosal changes of residents in the high incidence area of gastric cancer].
    Zhang XH; Huang B; Wang JL; Li YH; Mi JM; Shen HT; Zhang ZG; Yan X; Xing LX; Wang SJ
    Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):507-11. PubMed ID: 17147114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.